Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Dynavax Technologies Corporation

Share:
Related DVAX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
William Blair's Top BioPharma Stock Picks For Q1 2015
Oversight board recommends continuing Heplisav-B Phase 3 trial (Seeking Alpha)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Dynavax Technologies Corporation (NASDAQ: DVAX), but slightly lowered its price target from $6.00 to $5.00.

Jefferies noted, “A FDA panel voted 13-1 on the efficacy data and 5-8 on the safety data for Heplisav, DVAX's hepatitis B vaccine, in adults 18-70. The mixed safety vote was an unexpected negative, given the benign briefing documents and FDA presentation. We are lowering our PT from $6 to $5, but with the stock indicated at $2, we see DVAX as a risky but compelling buy at current levels as we see the market completely discounting near-term approval.”

Dynavax Technologies Corporation closed on Thursday at $4.63.

Latest Ratings for DVAX

DateFirmActionFromTo
Nov 2013McNicoll Lewis VlakUpgradesHoldBuy
Nov 2013JefferiesReiteratesBuy
Jun 2013JefferiesMaintainsBuy

View More Analyst Ratings for DVAX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DVAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→